ArticleCureus2026
Beyond the Skin: Chylous Pleural Effusion Complicating HIV-Associated Kaposi Sarcoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kaposi sarcoma (KS) is an HHV-8-mediated vascular malignancy encompassing four distinct clinical variants: classic, endemic, iatrogenic, and AIDS-associated. While classically indolent, KS can pursue an aggressive course in the context of HIV infection. Pleural involvement, particularly chylous effusion, represents a rare but grave manifestation of the disease. In cases of chylous effusion, pleural fluid analysis typically reveals a triglyceride concentration >110 mg/dL or the presence of chylomicrons, findings that signify true chylous involvement. We report the case of a 33-year-old man with AIDS-associated KS complicated by chylous pleural effusion. The patient was initiated on antiretroviral therapy and received a single dose of chemotherapy, after which he developed biochemical evidence of tumor lysis syndrome 16 days later, leading to fatal clinical deterioration. This case underscores the catastrophic potential of KS complicated by chylous pleural effusion and highlights the importance of vigilance for life-threatening complications during therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.